Rocket Pharmaceuticals Warrant
RCKTW
11 hedge funds and large institutions have $133K invested in Rocket Pharmaceuticals Warrant in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
10% more funds holding
Funds holding: 10 → 11 (+1)
19% less capital invested
Capital invested by funds: $164K → $133K (-$30.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4 |
| 2 |
CS
Clear Street
New York
|
+$1 |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$84 |
RCKTW Hedge Fund Activity: Q2 2026 in Review
11 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals Warrant (RCKTW) for Q2 2026, worth a combined $133K — down 19% from $164K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new RCKTW positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $4. The largest seller was UBS Group, exiting entirely with an estimated $84 sold.
- 11 institutional investors held Rocket Pharmaceuticals Warrant (RCKTW) as of Q2 2026, up from 10 in Q1 2026.
- Funds reported $133K of Rocket Pharmaceuticals Warrant stock for Q2 2026, down 19% quarter-over-quarter.
- 2 funds opened new Rocket Pharmaceuticals Warrant positions in Q2 2026 and 1 closed out, a net change of +1 holder.
- The largest Rocket Pharmaceuticals Warrant buyer in Q2 2026 was Citadel Advisors, an estimated $4 added.
- The largest Rocket Pharmaceuticals Warrant seller in Q2 2026 was UBS Group, an estimated $84 sold.
Based on aggregated 13F filings for Q2 2026.